Trial reportRetina (Philadelphia, Pa.)2010
Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema.
Trial report in Retina (Philadelphia, Pa.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study: Baseline Analysis of 24 Aqueous Cytokines.Ophthalmology science · 2026Article
- Prostanoid signaling in retinal cells elicits inflammatory responses relevant to early-stage diabetic retinopathy.Journal of neuroinflammation · 2024Article
- Inflammation in diabetes complications: molecular mechanisms and therapeutic interventions.MedComm · 2024Review
- Eicosanoids and Oxidative Stress in Diabetic Retinopathy.Antioxidants (Basel, Switzerland) · 2020Review
- PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.Journal of the American Society of Nephrology : JASN · 2016Review
- Lipid mediators are critical in resolving inflammation: a review of the emerging roles of eicosanoids in diabetes mellitus.BioMed research international · 2015Review
- The safety, pharmacokinetics, and efficacy of intraocular celecoxib.Investigative ophthalmology & visual science · 2014Article
- Modified Lipoproteins in Diabetic Retinopathy: A Local Action in the Retina.Journal of clinical & experimental ophthalmology · 2013Article
- Neuropeptides and diabetic retinopathy.British journal of clinical pharmacology · 2013Review
- Topical nonsteroidal anti-inflammatory drugs for macular edema.Mediators of inflammation · 2013Review
- Nonsteroidal anti-inflammatory drugs for retinal disease.International journal of inflammation · 2013Article
- Diabetic macular edema: therapeutic options.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2012Article
- Hydrophilic prodrug approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib.Molecular pharmaceutics · 2012Article
- Emerging pharmacotherapies for diabetic macular edema.Experimental diabetes research · 2012Review
- Lipid metabolites in the pathogenesis and treatment of neovascular eye disease.The British journal of ophthalmology · 2011Review
- Effect of systemic medications on onset and progression of diabetic retinopathy.Nature reviews. Endocrinology · 2010Review
- Systemic medical management of diabetic retinopathy.Middle East African journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 2 countries.
Funding
Abstract
purposeInflammation may play an important role in the pathogenesis of diabetic macular edema, a major cause of vision loss in persons with diabetes. The purpose of this study was to evaluate combined antiinflammatory therapy and laser approaches for treating patients with diabetic macular edema.
methodsIn this prospective, factorial, randomized, multicenter trial, we compared cyclo-oxygenase-2 inhibitor (celecoxib) with placebo and diode grid laser with standard Early Treatment Diabetic Retinopathy Study focal laser treatment in 86 participants with diabetic macular edema. The primary outcome is change in visual acuity of > or = 15 letters from baseline, and the secondary outcomes include a 50% reduction in the retinal thickening of diabetic macular edema measured by optical coherence tomography and a 50% reduction in leakage severity on fluorescein angiography.
resultsVisual acuity and retinal thickening data from >2 years of follow-up did not show evidence of differences between the medical and laser treatments. However, participants assigned to the celecoxib group were more likely to have a reduction in fluorescein leakage when compared with the placebo group (odds ratio = 3.6; P < 0.01).
conclusionThis short-term study did not find large visual function benefits of treatment with celecoxib or diode laser compared with those of standard laser treatment. A suggestive effect of celecoxib in reducing fluorescein leakage was observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.